Search Results - "Kurmasheva, Raushan T"

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia by Khaw, Seong Lin, Suryani, Santi, Evans, Kathryn, Richmond, Jennifer, Robbins, Alissa, Kurmasheva, Raushan T., Billups, Catherine A., Erickson, Stephen W., Guo, Yuelong, Houghton, Peter J., Smith, Malcolm A., Carol, Hernan, Roberts, Andrew W., Huang, David C.S., Lock, Richard B.

“…The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potential…”
Get full text

Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program by Kurmasheva, Raushan T., Sammons, Melissa, Favours, Edward, Wu, Jianwrong, Kurmashev, Dias, Cosmopoulos, Katherine, Keilhack, Heike, Klaus, Christine R., Houghton, Peter J., Smith, Malcolm A.

“…Background Tazemetostat (EPZ‐6438) is a selective inhibitor of the histone methyltransferase EZH2 and currently in clinical development for non‐Hodgkin…”
Get full text

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models by Lowery, Caitlin D, Dowless, Michele, Renschler, Matthew, Blosser, Wayne, VanWye, Alle B, Stephens, Jennifer R, Iversen, Philip W, Lin, Aimee Bence, Beckmann, Richard P, Krytska, Kateryna, Cole, Kristina A, Maris, John M, Hawkins, Douglas S, Rubin, Brian P, Kurmasheva, Raushan T, Houghton, Peter J, Gorlick, Richard, Kolb, E Anders, Kang, Min H, Reynolds, C Patrick, Erickson, Stephen W, Teicher, Beverly A, Smith, Malcolm A, Stancato, Louis F

“…Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA-damaging effects of cytotoxic therapies and/or promote elevated levels of replication stress, leading…”
Get full text

Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer by He, Funan, Bandyopadhyay, Abhik M., Klesse, Laura J., Rogojina, Anna, Chun, Sang H., Butler, Erin, Hartshorne, Taylor, Holland, Trevor, Garcia, Dawn, Weldon, Korri, Prado, Luz-Nereida Perez, Langevin, Anne-Marie, Grimes, Allison C., Sugalski, Aaron, Shah, Shafqat, Assanasen, Chatchawin, Lai, Zhao, Zou, Yi, Kurmashev, Dias, Xu, Lin, Xie, Yang, Chen, Yidong, Wang, Xiaojing, Tomlinson, Gail E., Skapek, Stephen X., Houghton, Peter J., Kurmasheva, Raushan T., Zheng, Siyuan

“…Subcutaneous patient-derived xenografts (PDXs) are an important tool for childhood cancer research. Here, we describe a resource of 68 early passage PDXs…”
Get full text

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report by Kolb, E. Anders, Houghton, Peter J., Kurmasheva, Raushan T., Mosse, Yael P., Maris, John M., Erickson, Stephen W., Guo, Yuelong, Teicher, Beverly A., Smith, Malcolm A., Gorlick, Richard

“…Introduction WEE1 is a serine kinase central to the G2 checkpoint. Inhibition of WEE1 can lead to cell death by permitting cell‐cycle progression despite…”
Get full text

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia by Richmond, Jennifer, Carol, Hernan, Evans, Kathryn, High, Laura, Mendomo, Agnes, Robbins, Alissa, Meyer, Claus, Venn, Nicola C, Marschalek, Rolf, Henderson, Michelle, Sutton, Rosemary, Kurmasheva, Raushan T, Kees, Ursula R, Houghton, Peter J, Smith, Malcolm A, Lock, Richard B

“…Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage…”
Get full text

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program by Kolb, E. Anders, Gorlick, Richard, Reynolds, C. Patrick, Kang, Min H., Carol, Hernan, Lock, Richard, Keir, Stephen T., Maris, John M., Billups, Catherine A., DesJardins, Christopher, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.

“…Background Antimitotic agents are essential components for curative therapy of pediatric acute leukemias and many solid tumors. Eribulin is a novel agent that…”
Get full text

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2 by Bid, Hemant K, Zhan, Jun, Phelps, Doris A, Kurmasheva, Raushan T, Houghton, Peter J

“…Previously, we reported that a predominant action of a type-1 insulin-like growth factor receptor (IGF-1R)-targeted antibody was through inhibiting…”
Get full text

PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair by Cropper, Jodie D, Alimbetov, Dauren S, Brown, Kevin T. G, Likhotvorik, Rostislav I, Robles, Andrew J, Guerra, James T, He, Boxue, Chen, Yidong, Kwon, Youngho, Kurmasheva, Raushan T

“…Abstract DNA lesions induced by alkylating agents are repaired by two canonical mechanisms, base excision repair dependent on poly(ADP) ribose polymerase 1…”
Get full text

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia by Suryani, Santi, Bracken, Lauryn S, Harvey, Richard C, Sia, Keith C S, Carol, Hernan, Chen, I-Ming, Evans, Kathryn, Dietrich, Philipp A, Roberts, Kathryn G, Kurmasheva, Raushan T, Billups, Catherine A, Mullighan, Charles G, Willman, Cheryl L, Loh, Mignon L, Hunger, Stephen P, Houghton, Peter J, Smith, Malcolm A, Lock, Richard B

“…Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The…”
Get full text

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program by Kolb, E. Anders, Gorlick, Richard, Billups, Catherine A., Hawthorne, Thomas, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.

“…Background Glembatumumab vedotin is an antibody‐auristatin conjugate that targets cells expressing the transmembrane glycoprotein NMB (GPNMB, also known as…”
Get full text

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma by Phelps, Doris, Bondra, Kathryn, Seum, Star, Chronowski, Christopher, Leasure, Justin, Kurmasheva, Raushan T., Middleton, Steven, Wang, Dian, Mo, Xiaokui, Houghton, Peter J.

“…Background Curative therapy for childhood sarcoma presents challenges when complete resection is not possible. Ionizing radiation (XRT) is used as a standard…”
Get full text

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma by Del Pozo, Vanessa, Robles, Andrew J., Fontaine, Shaun D., Liu, Qianqian, Michalek, Joel E., Houghton, Peter J., Kurmasheva, Raushan T.

“…Current therapy is ineffective for relapsed and metastatic Ewing sarcoma (EwS) owing to development of drug resistance. Macromolecular prodrugs potentially…”
Get full text

Comprehensive characterization of patient-derived xenograft models of pediatric leukemia by Rogojina, Anna, Klesse, Laura J., Butler, Erin, Kim, Jiwoong, Zhang, He, Xiao, Xue, Guo, Lei, Zhou, Qinbo, Hartshorne, Taylor, Garcia, Dawn, Weldon, Korri, Holland, Trevor, Bandyopadhyay, Abhik, Prado, Luz Perez, Wang, Shidan, Yang, Donghan M., Langevan, Anne-Marie, Zou, Yi, Grimes, Allison C., Assanasen, Chatchawin, Gidvani-Diaz, Vinod, Zheng, Siyuan, Lai, Zhao, Chen, Yidong, Xie, Yang, Tomlinson, Gail E., Skapek, Stephen X., Kurmasheva, Raushan T., Houghton, Peter J., Xu, Lin

“…Patient-derived xenografts (PDX) remain valuable models for understanding the biology and for developing novel therapeutics. To expand current PDX models of…”
Get full text

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program by Carol, Hernan, Gorlick, Richard, Kolb, E. Anders, Morton, Christopher L., Manesh, Donya Moradi, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Maris, John M., Wozniak, Amy, Hickson, Ian, Lyalin, Dmitry, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A., Lock, Richard

“…Background Quisinostat (JNJ‐26481585) is a second‐generation pyrimidyl‐hydroxamic acid histone deacetylase (HDAC) inhibitor with high cellular potency towards…”
Get full text

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors by Kurmasheva, Raushan T, Harwood, Franklin C, Houghton, Peter J

“…Levels of vascular endothelial growth factor (VEGF) are regulated, in part, through activation of the phosphatidylinositol 3′-kinase/Akt pathway. Using…”
Get full text

Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program by Gorlick, Richard, Maris, John M., Houghton, Peter J., Lock, Richard, Carol, Hernan, Kurmasheva, Raushan T., Kolb, E. Anders, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Billups, Catherine A., Smith, Malcolm A.

“…Background MK‐2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. Procedures MK‐2206 was…”
Get full text

Challenges and Opportunities for Childhood Cancer Drug Development by Houghton, Peter J, Kurmasheva, Raushan T

“…Cancer in children is rare with approximately 15,700 new cases diagnosed in the United States annually. Through use of multimodality therapy (surgery,…”
Get full text

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program by Keir, Stephen T., Maris, John M., Reynolds, C. Patrick, Kang, Min H., Kolb, E. Anders, Gorlick, Richard, Lock, Richard, Carol, Hernan, Morton, Christopher L., Wu, Jianrong, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.

“…Background The DNA methylating agent temozolomide was developed primarily for treatment of glioblastoma. However, preclinical data have suggested a broader…”
Get full text

In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium by Kurmasheva, Raushan T., Erickson, Stephen W., Earley, Eric, Smith, Malcolm A., Houghton, Peter J.

“…The Pediatric Preclinical Testing Program (PPTP) previously reported the activity of the EZH2 inhibitor tazemetostat (EPZ6438) against xenograft models of…”
Get full text